Effects of Potent Antiretroviral Therapy on the Immune Activation Marker Soluble CD27 in Patients Infected with HIV-1 Subtypes A-D

Journal of Medical Virology

Volumn 72, Issue 3, 2004, Pages 345-351

  Atlas, Ann ^a,b   Ha, Tran Thi Thanh ^a   Lindström, Anna ^c   Nilsson, Anna ^a,c   Alaeus, Annette ^b   Chiodi, Francesca ^a   De Milito, Angelo ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

ART; Disease progression; HIV genetic subtypes; Immune activation; Soluble markers

Indexed keywords

ANTIRETROVIRUS AGENT; CD27 ANTIGEN; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFECT; DRUG POTENCY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; NONHUMAN; POPULATION; TREATMENT OUTCOME; VIRAL GENETICS; VIRUS STRAIN;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 1642579713     PISSN: 01466615     EISSN: None     Source Type: Journal    
DOI: 10.1002/jmv.20006     Document Type: Article

References (33)

1. Alaeus A, Lidman K, Bjorkman A, Giesecke J, Albert J. 1999. Similar rate of disease progression among individuals infected with HIV-1 genetic subtypes A-D. AIDS 13:901-907.
2. Alexander CS, Montessori V, Wynhoven B, Dong W, Chan K, O'Shaughnessy MV, Mo T, Piaseczny M, Montaner JS, Harrigan PR. 2002. Prevalence and response to antiretroviral therapy of non-B subtypes of HIV in antiretroviral-naive individuals in British Columbia. Antivir Ther 7:31-35.
3. Amornkul PN, Tansuphasawadikul S, Limpakarnjanarat K, Likanonsakul S, Young N, Eampokalap B, Kaewkungwal J, Naiwatanakul T, Von Bargen J, Hu DJ, Mastro TD. 1999. Clinical disease associated with HIV-1 subtype B′ and E infection among 2104 patients in Thailand. AIDS 13:1963-1969.
4. Bentwich Z, Kalinkovich A, Weisman Z. 1995. Immune activation is a dominant factor in the pathogenesis of African AIDS. Immunol Today 16:187-191.
5. Carcelain G, Debre P, Autran B. 2001. Reconstitution of CD4+ T lymphocytes in HIV-infected individuals following antiretroviral therapy. Curr Opin Immunol 13:483-488.
6. Caride E, Brindeiro R, Hertogs K, Larder B, Dehertogh P, Machado E, de Sa CA, Eyer-Silva WA, Sion FS, Passioni LF, Menezes JA, Calazans AR, Tanuri A. 2000. Drug-resistant reverse transcriptase genotyping and phenotyping of B and non-B subtypes (F and A) of human immunodeficiency virus type I found in Brazilian patients failing HAART. Virology 275:107-115.
7. De Milito A, Aleman S, Marenzi R, Sonnerborg ADF, Zazzi M, Chiodi F. 2002. Plasma levels of soluble CD27: A simple marker to monitor immune activation during potent antiretroviral therapy in HIV-1infected subjects. Clin Exp Immunol 127:486-494.
8. De Milito A, Titanji K, Zazzi M. 2003. Surrogate markers as a guide to evaluate response to antiretroviral therapy. Curr Med Chem 10:349-365.
9. Font J, Pallares L, Martorell J, Martinez E, Gaya A, Vives J, Ingelmo M. 1996. Elevated soluble CD27 levels in serum of patients with systemic lupus erythematosus. Clin Immunol Immunopathol 81:239-243.
10. Frater AJ, Beardall A, Ariyoshi K, Churchill D, Galpin S, Clarke JR, Weber JN, McClure MO. 2001. Impact of baseline polymorphisms in RT and protease on outcome of highly active antiretroviral therapy in HIV-1-infected African patients. AIDS 15:1493-1502.
11. Frater AJ, Dunn DT, Beardall AJ, Ariyoshi K, Clarke JR, McClure MO, Weber JN. 2002. Comparative response of African HIV-1-infected individuals to highly active antiretroviral therapy. AIDS 16:1139-1146.
12. Janssens W, Buve A, Nkengasong JN. 1997. The puzzle of HIV-1 subtypes in Africa. AIDS 11:705-712.
13. Kaleebu P, Ross A, Morgan D, Yirrell D, Oram J, Rutebemberwa A, Lyagoba F, Hamilton L, Biryahwaho B, Whitworth J. 2001. Relationship between HIV-1 Env subtypes A and D and disease progression in a rural Ugandan cohort. AIDS 15:293-299.
14. Kaleebu P, French N, Mahe C, Yirrell D, Watera C, Lyagoba F, Nakiyingi J, Rutebemberwa A, Morgan D, Weber J, Gilks C, Whitworth J. 2002. Effect of human immunodeficiency virus (HIV) type 1 envelope subtypes A and D on disease progression in a large cohort of HIV-1-positive persons in Uganda. J Infect Dis 185:1244-1250.
15. Kanki PJ, Hamel DJ, Sankale JL, Hsieh C, Thior I, Barin F, Woodcock SA, Gueye-Ndiaye A, Zhang E, Montano M, Siby T, Marlink R, I ND, Essex ME, S MB. 1999. Human immunodeficiency virus type 1 subtypes differ in disease progression. J Infect Dis 179:68-73.
16. Lawn SD, Butera ST, Folks TM. 2001. Contribution of immune activation to the pathogenesis and transmission of human immunodeficiency virus type 1 infection. Clin Microbiol Rev 14:753-777 (table of contents).
17. Leitner T, Korovina G, Marquina S, Smolskaya T, Albert J. 1996. Molecular epidemiology and MT-2 cell tropism of Russian HIV type 1 variant. AIDS Res Hum Retroviruses 12:1595-1603.
18. Lens SM, Tesselaar K, van Oers MH, van Lier RA. 1998. Control of lymphocyte function through CD27-CD70 interactions. Semin Immunol 10:491-499.
19. Lindstrom A, Albert J. 2003. A simple and sensitive 'in-house' method for determining genotypic drug resistance in HIV-1. J Virol Methods 107:45-51.
20. Messele T, Brouwer M, Girma M, Fontanet AL, Miedema F, Hamann D, Rinke de Wit TF. 2001. Plasma levels of viro-immunological markers in HIV-infected and non-infected Ethiopians: Correlation with cell surface activation markers. Clin Immunol 98:212-219.
21. Montano MA, Nixon CP, Ndung'u T, Bussmann H, Novitsky VA, Dickman D, Essex M. 2000. Elevated tumor necrosis factor-alpha activation of human immunodeficiency virus type 1 subtype C in Southern Africa is associated with an NF-kappaB enhancer gain-of-function. J Infect Dis 181:76-81.
22. Neilson JR, John GC, Carr JK, Lewis P, Kreiss JK, Jackson S, Nduati RW, Mbori-Ngacha D, Panteleeff DD, Bodrug S, Giachetti C, Bott MA, Richardson BA, Bwayo J, Ndinya-Achola J, Overbaugh J. 1999. Subtypes of human immunodeficiency virus type 1 and disease stage among women in Nairobi, Kenya. J Virol 73:4393-4403.
23. Palmer S, Alaeus A, Albert J, Cox S. 1998. Drug susceptibility of subtypes A, B, C, D, and E human immunodeficiency virus type 1 primary isolates. AIDS Res Hum Retroviruses 14:157-162.
24. Pillay D, Walker AS, Gibb DM, de Rossi A, Kaye S, Ait-Khaled M, Munoz-Fernandez M, Babiker A. 2002. Impact of human immunodeficiency virus type 1 subtypes on virologic response and emergence of drug resistance among children in the Paediatric European Network for Treatment of AIDS (PENTA) 5 trial. J Infect Dis 186:617-625.
25. Rizzardini G, Piconi S, Ruzzante S, Fusi ML, Lukwiya M, Declich S, Tamburini M, Villa ML, Fabiani M, Milazzo F, Clerici M. 1996. Immunological activation markers in the serum of African and European HIV-seropositive and seronegative individuals. AIDS 10:1535-1542.
26. Rizzardini G, Trabattoni D, Saresella M, Piconi S, Lukwiya M, Declich S, Fabiani M, Ferrante P, Clerici M. 1998. Immune activation in HIV-infected African individuals. Italian-Ugandan AIDS cooperation program. AIDS 12:2387-2396.
27. Shafer RW, Eisen JA, Merigan TC, Katzenstein DA. 1997. Sequence and drug susceptibility of subtype C reverse transcriptase from human immunodeficiency virus type 1 seroconverters in Zimbabwe. J Virol 71:5441-5448.
28. Sousa AE, Carneiro J, Meier-Schellersheim M, Grossman Z, Victorino RM. 2002. CD4 T cell depletion is linked directly to immune activation in the pathogenesis of HIV-1 and HIV-2 but only indirectly to the viral load. J Immunol 169:3400-3406.
29. Spira S, Wainberg MA, Loemba H, Turner D, Brenner BG. 2003. Impact of clade diversity on HIV-1 virulence, antiretroviral drug sensitivity, and drug resistance. J Antimicrob Chemother 51:229-240.
30. Van de Peer Y, De Wachter R. 1994. TREECON for Windows: A software package for the construction and drawing of evolutionary trees for the Microsoft Windows environment. Comput Appl Biosci 10:569-570.
31. van Lier RA, Borst J, Vroom TM, Klein H, Van Mourik P, Zeijlemaker WP, Melief CJ. 1987. Tissue distribution and biochemical and functional properties of Tp55 (CD27), a novel T cell differentiation antigen. J Immunol 139:1589-1596.
32. Weisman Z, Kalinkovich A, Borkow G, Stein M, Greenberg Z, Bentwich Z. 1999. Infection by different HIV-1 subtypes (B and C) results in a similar immune activation profile despite distinct immune backgrounds. J Acquir Immune Defic Syndr 21:157-163.
33. Widney D, Gundapp G, Said JW, van der Meijden M, Bonavida B, Demidem A, Trevisan C, Taylor J, Detels R, Martinez-Maza O. 1999. Aberrant expression of CD27 and soluble CD27 (sCD27) in HIV infection and in AIDS-associated lymphoma. Clin Immunol 93:114-123.